Clinical trialUNITERAREApr 3
Researchers are testing a new drug called Xaluritamig to treat Ewing sarcoma, a rare bone cancer that has come back or stopped responding to previous treatments. This is an early-stage study (Phase 1) that will include children, teenagers, and adults. The study is now accepting patients and is expected to start in April 2026.
WHY IT MATTERSThis trial offers a potential new treatment option for patients with relapsed or refractory Ewing sarcoma, a rare pediatric cancer with limited treatment alternatives after standard therapies fail.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new cancer drug called CLR 131 in children and young adults whose cancers have come back or stopped responding to standard treatments. The study includes kids with several types of hard-to-treat cancers like neuroblastoma, sarcomas, and brain tumors. This is an early-stage study to figure out the right dose and see if the drug is safe and effective.
WHY IT MATTERSThis trial offers a potential treatment option for children with relapsed or refractory neuroblastoma, sarcomas, and other pediatric solid tumors where standard treatments have failed—conditions with very limited curative options.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a drug called cabozantinib-s-malate to treat children and young adults with rare cancers, including sarcomas (muscle cancers), Wilms tumor (kidney cancer), and other solid tumors that have come back after treatment or didn't respond to initial therapy. The drug works by blocking proteins that help tumors grow and form new blood vessels. This phase II trial has enrolled 109 patients and is no longer recruiting new participants.
WHY IT MATTERSIf your child has a recurrent or treatment-resistant sarcoma, Wilms tumor, or other rare pediatric solid tumor, this completed trial data may help inform whether cabozantinib could be an option to discuss with their oncologist.